Clinical value of <sup>18</sup> F‐PI2620‐PET in the diagnostic workup of patients with suspected Progressive Supranuclear Palsy
<sup>18</sup>F-PI-2620 tau-PET can successfully identify patients that progress along expected 4RT clinical spectra. This supports <sup>18</sup>F-PI-2620 tau-PET as a 4RT biomarker, with the potential to facilitate early biomarker-based diagnosis when clinical criteria may still lack sensitivity and specificity. This development can be transformative for clinical decision making, pre-symptomatic identification of PSP and stratifying patients for disease modifying clinical trials.
Authors
- Endy Weidinger (ORCID: https://orcid.org/0009-0003-6679-7788)
- Johannes Levin (ORCID: https://orcid.org/0000-0001-5092-4306)
- Carla Palleis (ORCID: https://orcid.org/0000-0002-4331-8145)
- Osama Sabri
- Johannes Gnörich (ORCID: https://orcid.org/0000-0003-1554-7765)
- Urban M. Fietzek (ORCID: https://orcid.org/0000-0002-4323-9930)
- Sabrina Katzdobler (ORCID: https://orcid.org/0000-0002-3512-5984)
- Andreas Zwergal (ORCID: https://orcid.org/0000-0002-3839-8398)
- Nicolai Franzmeier (ORCID: https://orcid.org/0000-0001-9736-2283)
- Sebastian N. Roemer‐Cassiano
- Henryk Barthel
- Lukas Frontzkowski
- Alexander Jäck
- Günter U Höglinger
- Matthias Brendel
- Alexander M Bernhardt
Institutions
- German Center for Neurodegenerative Diseases (DE)
- LMU Klinikum (DE)
- Munich Cluster for Systems Neurology (DE)
- Max Planck Institute for Human Cognitive and Brain Sciences (DE)
- Schön Klinik München Schwabing (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Gothenburg (SE)
- Leipzig University (DE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_102121
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00